TY - JOUR
KW - Analgesics, Opioid/administration & dosage/adverse effects
KW - Animals
KW - Buprenorphine/administration & dosage
KW - Female
KW - Humans
KW - Infant, Newborn
KW - Methadone/administration & dosage
KW - Opiate Substitution Treatment/methods
KW - Opioid-Related Disorders/complications/drug therapy
KW - Pregnancy
KW - Pregnancy Complications/drug therapy
AU - C. M. Wilder
AU - T. Winhusen
A1 - 
AB - Opioid misuse during pregnancy is associated with negative outcomes for both mother and fetus due not only to the physiological effects of the drug but also to the associated social, medical and mental health problems that accompany illicit drug use. An interdisciplinary approach to the treatment of opioid use disorder during pregnancy is most effective. Ideally, obstetric and substance use treatment are co-located and ancillary support services are readily available. Medication-assisted treatment with methadone or buprenorphine is intrinsic to evidence-based care for the opioid-using pregnant woman. Women who are not stabilized on an opioid maintenance medication experience high rates of relapse and worse outcomes. Methadone has been the mainstay of maintenance treatment for nearly 50 years, but recent research has found that both methadone and buprenorphine maintenance treatments significantly improve maternal, fetal and neonatal outcomes. Although methadone remains the current standard of care, the field is beginning to move towards buprenorphine maintenance as a first-line treatment for pregnant women with opioid use disorder, because of its greater availability and evidence of better neonatal outcomes than methadone. However, there is some evidence that treatment dropout may be greater with buprenorphine relative to methadone.
BT - CNS drugs
C5 - Opioids & Substance Use
CP - 8
CY - New Zealand
DO - 10.1007/s40263-015-0273-8
IS - 8
JF - CNS drugs
N2 - Opioid misuse during pregnancy is associated with negative outcomes for both mother and fetus due not only to the physiological effects of the drug but also to the associated social, medical and mental health problems that accompany illicit drug use. An interdisciplinary approach to the treatment of opioid use disorder during pregnancy is most effective. Ideally, obstetric and substance use treatment are co-located and ancillary support services are readily available. Medication-assisted treatment with methadone or buprenorphine is intrinsic to evidence-based care for the opioid-using pregnant woman. Women who are not stabilized on an opioid maintenance medication experience high rates of relapse and worse outcomes. Methadone has been the mainstay of maintenance treatment for nearly 50 years, but recent research has found that both methadone and buprenorphine maintenance treatments significantly improve maternal, fetal and neonatal outcomes. Although methadone remains the current standard of care, the field is beginning to move towards buprenorphine maintenance as a first-line treatment for pregnant women with opioid use disorder, because of its greater availability and evidence of better neonatal outcomes than methadone. However, there is some evidence that treatment dropout may be greater with buprenorphine relative to methadone.
PP - New Zealand
PY - 2015
SN - 1172-7047; 1172-7047
SP - 625
EP - 636
EP - 
T1 - Pharmacological Management of Opioid Use Disorder in Pregnant Women
T2 - CNS drugs
TI - Pharmacological Management of Opioid Use Disorder in Pregnant Women
U1 - Opioids & Substance Use
U2 - 26315948
U3 - 10.1007/s40263-015-0273-8
VL - 29
VO - 1172-7047; 1172-7047
Y1 - 2015
ER -